Stocks scoring 25–45 beat the S&P 500
45.3% of the time over the next three months, since 2015.
How we measured this →
8
hedge funds
hold it · 1 new, 4 added, 2 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$257M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About ROCKET PHARMACEUTICALS INC
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive…
Who's behind the signal
Every informed buyer we can see on RCKT, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ROCKET PHARMACEUTICALS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
4
Increasing
2
Decreasing
1
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to ROCKET PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ROCKET PHARMACEUTICALS INC or any security.